Health Canada's investment in new post-market drug surveillance network a "pittance"

Silversides, Ann
August 2008
CMAJ: Canadian Medical Association Journal;8/26/2008, Vol. 179 Issue 5, p412
Academic Journal
The article focuses on the $1 million investment by Health Canada in an independent research network that will study the safety and effects of prescription drugs taken by Canadians. In June 2008, the Parliament's Standing Committee on Health called on the government to form the network that would link researchers around the country to produce timely reports that track the effect of drug use in the "real world" and hence, help protect Canadians from the unexpected adverse impacts of prescription drugs.


Related Articles

  • Canada Vigilance: a new name and database.  // WHO Drug Information;2008, Vol. 22 Issue 1, p18 

    The article announces the Canada Vigilance as the new name of the Canadian Adverse Drug Reaction Monitoring Program of the government health agency Health Canada in Canada in 2008. The program also implement its new database that will provide an enhanced capacity for the postmarketing...

  • Anticoagulant AEs could halve with improved INR control.  // Reactions Weekly;6/2/2007, Issue 1154, p1 

    The article discusses research being done on the effect of improved anticoagulation control on the incidence of anticoagulant-associated adverse effects. It references a study by Oake et al published in the May 22, 2007 issue of the "Canadian Medical Association Journal." Results showed that...

  • Medicines information provided by pharmaceutical representatives: a comparative study in Australia and Malaysia. Othman, Noordin; Vitry, Agnes I.; Roughead, Elizabeth E.; Ismail, Shaiful B.; Omar, Khairani // BMC Public Health;2010, Vol. 10 Issue 1, p743 

    Background: Pharmaceutical representatives provide medicines information on their promoted products to doctors. However, studies have shown that the quality of this information is often low. No study has assessed the medicines information provided by pharmaceutical representatives to doctors in...

  • SFINX—a drug-drug interaction database designed for clinical decision support systems. Böttiger, Ylva; Laine, Kari; Andersson, Marine; Korhonen, Tuomas; Molin, Björn; Ovesjö, Marie-Louise; Tirkkonen, Tuire; Rane, Anders; Gustafsson, Lars; Eiermann, Birgit // European Journal of Clinical Pharmacology;Jun2009, Vol. 65 Issue 6, p627 

    The aim was to develop a drug-drug interaction database (SFINX) to be integrated into decision support systems or to be used in website solutions for clinical evaluation of interactions. Key elements such as substance properties and names, drug formulations, text structures and references were...

  • THE BEST AND WORST DRUGS FOR WOMEN. Davis, Lisa; Burmeier, Beverly; von Bubnoff, Andreas // Prevention;Mar2007, Vol. 59 Issue 3, p167 

    This article explains that women are at increased risk for side effects from prescription drugs. The chemical make up of women contributes to the metabolizing of certain drugs. The author speaks of a gender based medicine where women are required to participate in all federally funded clinical...

  • Why Drug Safety Should Not Take a Back Seat to Efficacy.  // PLoS Medicine;Sep2011, Vol. 8 Issue 9, p1 

    The authors' reflect on the consideration given to the harmful effects from prescription drug use which can cause major adverse drug reactions and deaths. They refer to medical studies that suggest to improve the passive surveillance systems on drug safety concerns. However, the authors reveal...

  • Fatal ARs reported with fentanyl patch.  // Reactions Weekly;7/12/2008, Issue 1210, p3 

    The article reports that Health Canada has received 105 reports of adverse reactions (ARs) with a fatal outcome suspected of being associated with use of fentanyl transdermal patches for the period January 1, 1992 to December 31, 2007. According to the report, the cause of death was unrelated to...

  • Drug interaction a common problem in the clinical setting: Scenario of developing countries. Bhagavathula, Akshaya Srikanth; Sarkar, Barun Ranjan // Archives of Pharmacy Practice;Jul-Sep2014, Vol. 5 Issue 3, p137 

    A letter to the editor about drug-drug interactions is presented.

  • Info on paediatric drug safety released by Health Canada.  // Reactions Weekly;1/28/2012, Issue 1386, p3 

    The article deals with the reports received by Health Canada regarding cardiometabolic adverse events suspected of being related to the use of second-generation antipsychotics in children and adolescents aged 18 years and below.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics